Your Health, We Care
Another NameLuciNfig,Truseltiq,英菲格拉替尼,英飞替尼
IndicationsIt is indicated for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 gene abnormalities.
Reg No.04 L 1338/25
Inspection NO.835-25
Infigratinib, a targeted drug produced by Lucius Pharmaceuticals for specific genetic abnormalities, provides a relatively precise and effective treatment option for patients with cholangiocarcinoma.
The following is a summary of the main drug information for Infigratinib.
Its main active ingredient is Infigratinib Phosphate.
It is indicated for adult patients with unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusion or rearrangement who have received prior treatment.
The recommended dose is 125 mg orally once daily, taken consecutively for 21 days followed by a 7-day drug holiday, forming a 28-day treatment cycle; it should be administered on an empty stomach.
Dose adjustment is required for patients with mild to moderate renal impairment or hepatic impairment; it is contraindicated in pregnant and lactating women. Women of childbearing potential and men with partners of childbearing potential should use effective contraception during treatment and for 1 month after discontinuation of the drug.
The specific management measures for drug overdose are not clearly mentioned in the documentation. During use, the drug should be strictly administered in accordance with medical advice to prevent accumulation.
The drug should be stored sealed at room temperature between 20°C and 25°C, away from high temperatures or humidity.
The drug is slowly absorbed after oral administration, with a time to peak concentration of approximately 6 hours. It is mainly metabolized by CYP3A4, and both the parent drug and active metabolites exert pharmacological effects together.
FDA，2021.05
